N/A N=20 Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes
Assess Phenylephrine on EVP and IOP
Primary: Change in Episcleral Venous Pressure (EVP) — 7.2 mmHg — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=3,626 Norepinephrine vs Phenylephrine During General Anesthesia
Anesthesia · Surgery · Hypotension
Primary: Number of Participants With Assigned Vasopressor Given — 1570; 1627 Participants
N/A N=110 Phenylephrine in Spinal Anesthesia in Preeclamptic Patients
Preeclampsia · Hypotension
Primary: The Umbilical Artery pH — 7.22; 7.20 pH — p=.38
Phase 3 N=64 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
Mydriasis
Primary: Change in Pupil Diameter From Baseline — 2.672; 2.583; 2.657; 2.569 millimeters
Phase 4 N=18 Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
Phase 2 N=539 Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)
Rhinitis · Seasonal Rhinitis
Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score — -0.460; -0.499; -0.508; -0.461 Units on a Scale — p=0.4912
Phase 3 N=70 Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
Mydriasis
Primary: Change in Pupil Diameter From Baseline — 4.747; 4.779; 0.134; 0.032 millimeters
Phase 3 N=116 Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)
Blood Pressure · Human Experimentation
Primary: Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax). — 118.3; 118.6 mmHg — p=0.5480
Phase 2 N=39 Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure — -2.30; -2.18 mmHg — p=0.89
N/A N=68 The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
Epistaxis · Blood Pressure
Primary: Change in Mean Arterial Blood Pressure — 5.1; 6.4; 4.6; 6.5 mmHg — p=0.42
Phase 4 N=81 Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery
Effects of; Anesthesia, in Labor and Delivery
Primary: Number of Rescue Boluses to Maintain SBP — 25; 21 rescue boluses — p=0.12
Phase 4 N=35 Circadian Ocular Perfusion Pressure and Ocular Blood Flow
Glaucoma
Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)
Phase 3 N=153 Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:
Cardiac Disease
Primary: mPAP-to-MAP Ratio — 0.394; 0.385; 0.42; 0.40 ratio of mPAP-to-MAP — p=0.53
Phase 2 N=298 Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 25.11; 25.12; 25.35; 25.99 mmHg — p=<0.0001
Phase 3 N=39 The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)
Rhinitis, Allergic, Seasonal
Primary: The Average Change From Baseline to Endpoint (6 Hours Post-dosing) in Nasal Congestion for Phenylephrine Compared With Placebo — 2.20; 2.20; -0.12; -0.18 Units on a…
N/A N=27 The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
Glaucoma, Open-angle · Hypertension, Ocular
Primary: Change in Intraocular Pressure From Baseline at Visit 3 — 21.1; 18.2; 20.0; 17.1 mmHg
Phase 4 N=30 Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
Mydriasis
Primary: Mean Change in Pupil Diameter — 3.73; 6.46 millimeters
N/A N=30 Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption
Adenoidectomy · Functional Endoscopic Sinus Surgery (FESS) · Turbinate Surgery
Primary: Blood Pressure Following Oxymetazoline Administration — 102; 53; 65 mmHg
Phase 4 N=114 The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
Ptosis, Eyelid · Conjunctiva Inflamed · Eye Manifestations
Primary: Change in Palpebral Fissure Height — 1.1; -0.4 mm
N/A N=410 Post-Market Evaluation of the EVO ICL
Myopia · Myopic Astigmatism
Primary: Elevated Intraocular Pressure (IOP) in Primary Eyes ≥ 30 mmHg — 15 Eyes
Phase 2 N=68 A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
Glaucoma, Open-Angle
Primary: Mean Intraocular Pressure — 21.8; 20.5; 23.4; 19.7 mmHg
Phase 4 N=80 Variable Rate Phenylephrine Infusion for Prevention of Spinal-induced Hypotension for Cesarean Delivery
Anesthetic Complication Spinal
Primary: Number of Physician Interventions Needed to Maintain Maternal Blood Pressure After Spinal Anesthesia Within 20% of Baseline and to Treat Bradycardia During Cesarean…
Phase 3 N=185 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
Mydriasis · Dilation
Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 46; 6 Participants
N/A N=1,099 Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year — 20.8; 20.3; 20.6; -4.8 Millimeters of mercury (mmHg)
Phase 3 N=575 Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daily Reflective Nasal Congestion Score — 2.357; 2.271; -0.394; -0.412 Scores on a scale
Phase 2 N=67 Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028
Phase 2 N=323 Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure at Week 2 — 19.05; 18.92; 18.28; 17.86 mmHg
Phase 4 N=40 Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
Endoscopic Sinus Surgery · Nasal Polyps
Primary: Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale — 3; 2.55 score on a scale
Phase 2 N=241 A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Open-angle Glaucoma, Ocular Hypertension
Primary: Intraocular Pressure in the Study Eye at Month 3 — 18.8; 18.1; 19.7; 19.2 mmHg
Phase 2 N=31 A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 Ante Meridiem (AM) (0 Hour) — 22.77; 22.41; 5.00; 3.79 mmHg